BCG vaccine induces a broad innate immune-system response and has been shown to protect against infection. AP
The widely used BCG tuberculosis vaccine will be tested on frontline care workers in Britain for its effectiveness against COVID-19, researchers running the UK arm of a global trial said.
Bacillus Calmette-Guérin (BCG) vaccine, used to protect against tuberculosis, induces a broad innate immune-system response and has been shown to protect against infection or severe illness with other respiratory pathogens.
"BCG has been shown to boost immunity in a generalised way, which may offer some protection against COVID-19," Professor John Campbell, of the University of Exeter Medical School, said.
The UK study is part of an existing Australian-led trial has arms in the Netherlands, Spain and Brazil. File photo
"We are seeking to establish whether the BCG vaccine could help protect people who are at risk of COVID-19. If it does, we could save lives by administering or topping up this readily available and cost-effective vaccination."
The UK study is part of an existing Australian-led trial, which launched in April and also has arms in the Netherlands, Spain and Brazil. The BCG vaccine is also being tested as a protection against COVID-19 in South Africa.
The British trial is recruiting volunteers ahead of winter months that officials have warned may be tough as the country grapples with a second wave of infections.
UK Prime Minister Boris Johnson has indicated that restrictions to curb the pandemic could be in place until spring.
The trial's UK arm, which is being run from Exeter, southwest England, is seeking to recruit 1,000 people who work in care homes and community healthcare nearby.
Globally, more than 10,000 healthcare staff will be recruited.
The department of health said in a statement, “The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to approve Pfizer-BioNTech's Covid-19 vaccine for use."
No vaccine has yet been approved to treat or prevent COVID-19, the respiratory disease caused by the coronavirus that has killed more than 659,000 people and unleashed economic havoc worldwide.
A year into the pandemic, infection rates are falling. Hospitals are quieter; morgues are emptier. Emboldened by vaccines, we’re dropping our masks and stepping closer. Slowly we’re reopening indoor dining, theaters, museums and schools.
Afghanistan, Bangladesh and Nepal are among Asia's poorest nations by GDP per capita. In total, the World Bank had provided $12 billion for developing countries to procure and distribute Covid-19 vaccines, tests and treatments.
Tens of thousands of protesters marched in support of Palestinians on Saturday in major European cities including London, Berlin, Madrid and Paris.
The big winner was from Egypt, Asmaa Al Awani, who won the grand prize, a brand-new BMW car, while 5 shoppers won shopping worth Dhs5,000, 10 winners won Dhs2,500 shopping vouchers, and 10 lucky shoppers won a cash prize worth Dhs1,000 for each.
Cases have fallen steadily in some Indian states hit by an initial surge in infections, such as the richest state of Maharashtra and the capital New Delhi, after they imposed stringent lockdowns. Testing rates also at their lowest since Sunday.
The NCOC late last month announced a new set of restrictions including a blanket ban on tourism and inter-provincial transport in an attempt to contain a further rise in already mounting coronavirus cases under the "Stay Home, Stay Safe” strategy.